Cargando…
Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome
PURPOSE: Moyamoya syndrome (MMS) is a rare intracranial arterial vasculopathy which can occur in neurofibromatosis type 1 (NF1) disease, representing a cause of cerebrovascular reserve (CVR) impairment, possibly leading to ischemic stroke. Here, we evaluated noninvasive imaging techniques used to as...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843564/ https://www.ncbi.nlm.nih.gov/pubmed/32651859 http://dx.doi.org/10.1007/s10072-020-04574-4 |
_version_ | 1783644174416871424 |
---|---|
author | D’Amico, Alessandra Ugga, Lorenzo Cocozza, Sirio Giorgio, Sara Maria delle Acque Cicala, Domenico Santoro, Claudia Melis, Daniela Cinalli, Giuseppe Brunetti, Arturo Pappatà, Sabina |
author_facet | D’Amico, Alessandra Ugga, Lorenzo Cocozza, Sirio Giorgio, Sara Maria delle Acque Cicala, Domenico Santoro, Claudia Melis, Daniela Cinalli, Giuseppe Brunetti, Arturo Pappatà, Sabina |
author_sort | D’Amico, Alessandra |
collection | PubMed |
description | PURPOSE: Moyamoya syndrome (MMS) is a rare intracranial arterial vasculopathy which can occur in neurofibromatosis type 1 (NF1) disease, representing a cause of cerebrovascular reserve (CVR) impairment, possibly leading to ischemic stroke. Here, we evaluated noninvasive imaging techniques used to assess CVR in MMS patients, describing clinical and imaging findings in patients affected by MMS-NF1. METHODS: Following strict inclusion and exclusion criteria, in this retrospective observational study, we evaluated imaging data of nine consecutive MMS-NF1 patients (M/F = 5/4, mean age: 12.6 ± 4.0). Subjects underwent a multimodal evaluation of cerebral vascular status, including intracranial arterial MR Angiography (MRA), MRI perfusion with dynamic susceptibility contrast (DSC) technique, and 99mTc-hexamethylpropyleneamine oxime (HMPAO) SPECT. RESULTS: In 8 out 9 patients (88.8%, 6/8 symptomatic), time-to-peak maps were correlated with the involved cerebral hemisphere, while in 6 out 9 patients (66.6%, 5/6 symptomatic), mean transit time (MTT) maps showed correspondence with the affected cerebrovascular territories. Cerebral blood flow (CBF) calculated using DSC perfusion failed to detect the hypoperfused regions instead identified by SPECT-CBF in all patients, while MTT maps overlapped with SPECT-CBF data in all cases and time-to-peak maps in 60.0%. CONCLUSIONS: Although SPECT imaging still represents the gold standard for CBF assessment, our results suggest that data obtained using DSC perfusion technique, and in particular MTT maps, might be a very useful and noninvasive tool for evaluating hemodynamic status in MMS-NF1 patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10072-020-04574-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7843564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-78435642021-02-04 Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome D’Amico, Alessandra Ugga, Lorenzo Cocozza, Sirio Giorgio, Sara Maria delle Acque Cicala, Domenico Santoro, Claudia Melis, Daniela Cinalli, Giuseppe Brunetti, Arturo Pappatà, Sabina Neurol Sci Original Article PURPOSE: Moyamoya syndrome (MMS) is a rare intracranial arterial vasculopathy which can occur in neurofibromatosis type 1 (NF1) disease, representing a cause of cerebrovascular reserve (CVR) impairment, possibly leading to ischemic stroke. Here, we evaluated noninvasive imaging techniques used to assess CVR in MMS patients, describing clinical and imaging findings in patients affected by MMS-NF1. METHODS: Following strict inclusion and exclusion criteria, in this retrospective observational study, we evaluated imaging data of nine consecutive MMS-NF1 patients (M/F = 5/4, mean age: 12.6 ± 4.0). Subjects underwent a multimodal evaluation of cerebral vascular status, including intracranial arterial MR Angiography (MRA), MRI perfusion with dynamic susceptibility contrast (DSC) technique, and 99mTc-hexamethylpropyleneamine oxime (HMPAO) SPECT. RESULTS: In 8 out 9 patients (88.8%, 6/8 symptomatic), time-to-peak maps were correlated with the involved cerebral hemisphere, while in 6 out 9 patients (66.6%, 5/6 symptomatic), mean transit time (MTT) maps showed correspondence with the affected cerebrovascular territories. Cerebral blood flow (CBF) calculated using DSC perfusion failed to detect the hypoperfused regions instead identified by SPECT-CBF in all patients, while MTT maps overlapped with SPECT-CBF data in all cases and time-to-peak maps in 60.0%. CONCLUSIONS: Although SPECT imaging still represents the gold standard for CBF assessment, our results suggest that data obtained using DSC perfusion technique, and in particular MTT maps, might be a very useful and noninvasive tool for evaluating hemodynamic status in MMS-NF1 patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10072-020-04574-4) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-07-10 2021 /pmc/articles/PMC7843564/ /pubmed/32651859 http://dx.doi.org/10.1007/s10072-020-04574-4 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Article D’Amico, Alessandra Ugga, Lorenzo Cocozza, Sirio Giorgio, Sara Maria delle Acque Cicala, Domenico Santoro, Claudia Melis, Daniela Cinalli, Giuseppe Brunetti, Arturo Pappatà, Sabina Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome |
title | Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome |
title_full | Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome |
title_fullStr | Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome |
title_full_unstemmed | Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome |
title_short | Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome |
title_sort | multimodal evaluation of the cerebrovascular reserve in neurofibromatosis type 1 patients with moyamoya syndrome |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843564/ https://www.ncbi.nlm.nih.gov/pubmed/32651859 http://dx.doi.org/10.1007/s10072-020-04574-4 |
work_keys_str_mv | AT damicoalessandra multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome AT uggalorenzo multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome AT cocozzasirio multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome AT giorgiosaramariadelleacque multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome AT cicaladomenico multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome AT santoroclaudia multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome AT melisdaniela multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome AT cinalligiuseppe multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome AT brunettiarturo multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome AT pappatasabina multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome |